Evaluation and management of non-alcoholic steatohepatitis

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 11, 2004, Pages 1117-1122

  Reid, B Marie ^a   Sanyal, Arun J ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCV Box 980711 ^*  (United States)

Author keywords

Betaine; Liver biopsy; Metformin; Non alcoholic fatty liver; Non alcoholic steatohepatitis; Obesity; Orlistat; Pioglitazone; Rosiglitazone; Ursodeoxycholic acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; BETAINE; GEMFIBROZIL; METFORMIN; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; S ADENOSYLMETHIONINE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; EVALUATION; HUMAN; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT PLANNING; VIRUS HEPATITIS; WILSON DISEASE;

DIABETES COMPLICATIONS; FATTY LIVER; HEPATITIS; HUMANS; HYPERTENSION; LIVER; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 8444247110     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200411000-00005     Document Type: Review

References (39)

1. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2001; 9:37-51.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359. This survey examines the prevalence of the metabolic syndrome within the United States and stresses its possible clinical implications with end-organ disease.
3. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-1727. This study examines trends and prevalence of obesity in the United States. It found that both the obese and overweight populations continue to increase in the United States.
4. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21:17-26.
5. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123:1705-1725.
6. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103-1109. This was the first study to describe a series of patients with non-alcoholic steatohepatitis with a different clinical profile. The population consisted of a majority of non-obese men with normal glucose and lipid levels which differed from the previous study groups that consisted of obese, diabetic women.
7. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
8. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438. This is the classic study which first describes the entity of non-alcoholic steatohepatitis (NASH).
9. Haller DL, Sargeant CA, Luketic VA, Contos MJ, Sterling RK, Stravitz RT, et al. A behavioral analysis of nonalcoholic fatty liver disease: implications for the clinician. Hepatology 2003; 34:513A.
10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98:960-967.
11. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98:2064-2071.
12. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413-1419. One of the best studies evaluating the long-term outcomes in patients with NASH.
13. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94:1018-1022.
14. Yanai H, Morimoto M. Diagnosis of nonalcoholic fatty liver disease. JAMA 2003; 290:1577.
15. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750. One of the most succinct studies evaluating different imaging modalities in the evaluation of biopsy-proven NASH.
16. Nomura F, Ohnishi K, Ochiai T, Okuda K. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 1987; 162:845-847.
17. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3-16.
18. Naschitz JE, Yeshurun D, Zuckerman E, Arad E, Boss JH. Massive hepatic steatosis complicating adult celiac disease: report of a case and review of the literature. Am J Gastroenterol 1987; 82:1186-1189.
19. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37:1286-1292.
20. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158:1855-1867. This study gives definitive criteria of the definition, best modes of evaluation and treatment strageties for the obese population.
21. Bjorck I, Elmstahl HL. The glycaemic index: importance of dietary fibre and other food properties. Proc Nutr Soc 2003; 62:201-206.
22. Pereira MA, Liu S. Types of carbohydrates and risk of cardiovascular disease. J Womens Health (Larchmt) 2003; 12:115-122.
23. Ziegler O, Quilliot D, Guerci B, Drouin P. Macronutrients, fat mass, fatty acid flux and insulin sensitivity. Diabetes Metab 2001; 27:261-270.
24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403. This is a landmark study that defines the role of lifestyle intervention and pharmacological treatment of insulin resistance in the prevention of diabetes, a major complication of the metabolic syndrome.
25. Kriska A, Can a physically active lifestyle prevent type 2 diabetes? Exerc Sport Sci Rev 2003; 31:132-137.
26. Rollins G. Moderate exercise reduces the risk of heart disease and death in men with type 2 diabetes. Rep Med Guidelines Outcomes Res 2003; 14:10 and 12.
27. Hollander P. Orlistat in the treatment of obesity. Primary Care 2003; 30:427-440.
28. Holt R. Orlistat reduces features of the metabolic syndrome: the XENDOS study. Diabetes Obes Metab 2003; 5:356.
29. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27:1437-1446. Detailed analysis of all randomized controlled trials of weight loss therapies in the obese population.
30. Ryan DH. Use of sibutramine to treat obesity. Primary Care 2003; 30:405-426, and viii.
31. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003; 12:189-192.
32. Luyckx FH, Scheen AJ, Desaive C, Thiry A, Lefebvre PJ. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity. J Clin Endocrinol Metab 1999; 84:4293.
33. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, et al. Abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22:222-226.
34. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:519-525.
35. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38:1008-1017. Determines that insulin-sensitizing pharmacotherapy is important in the treatment of liver disease.
36. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358:893-894.
37. Lindor K. Ursodeoxycholic acid for nonalcoholic steatohepatitis: results of a randomized placebo-controlled trial. Gastroenterology 2003; 124:A708.
38. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734-738.
39. Cheung MC, Zhao XO, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin - niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001; 21:1320-1326.